Patents Assigned to GENEMEDICINE CO., LTD.
-
Patent number: 11970715Abstract: Disclosed is a pH-sensitive and bioreducible polymer-virus complex which can destroy tumor cells more effectively by increasing the efficiency of virus transduction. A pH-sensitive and bioreducible polymer contains (i) an escapable portion from immune reactions, (ii) a chargeable portion having one or more amine groups and (iii) a bioreducible portion including one or more disulfide linkages. The and to a pharmaceutical composition containing the polymer-virus complex. Also disclosed are a pharmaceutical composition containing the pH-sensitive and bioreducible polymer-virus complex and methods for treating cancer in a subject, employing the composition.Type: GrantFiled: September 27, 2021Date of Patent: April 30, 2024Assignee: GENEMEDICINE CO., LTD.Inventors: Chae Ok Yun, Dayananda Kasala
-
Publication number: 20240043796Abstract: A cell sheet for gene delivery is disclosed. Unlike conventional cell sheets for tissue regeneration, the disclosed cell sheet can be used as a local gene delivery system. Particularly when a virus is used as a gene delivery system, the virus can be proliferated within the cell sheet and acts topically within a therapeutic region. Thus, the cell sheet is superior in the prevention or treatment of cancer, the prevention of cancer recurrence or cancer metastasis, particularly the treatment of multifocal tumor even though the virus dose is remarkably lowered compared to the systemic administration or intratumoral injection of the virus.Type: ApplicationFiled: October 23, 2023Publication date: February 8, 2024Applicant: GeneMedicine Co., Ltd.Inventors: Chae Ok YUN, Tae Geuk KIM
-
Patent number: 11850215Abstract: The present invention relates to: recombinant adenoviruses, which have an excellent ability to be introduced into stem cells and can be easily introduced into stem cells even at a low concentration; stem cells comprising the same; a gene delivery composition; and a pharmaceutical composition. Stem cells into which adenoviruses are introduced, of the present invention, have excellent in vivo survivability and a treatment effect on tumor cells, and, when used as an anticancer drug, do not cause problems with respect to in vivo survival, hepatotoxicity and the like of stem cells so as to be particularly usable for systemic administration, and have an excellent anticancer effect even in small doses, thereby being widely usable as an anticancer drug using adenoviruses.Type: GrantFiled: December 12, 2018Date of Patent: December 26, 2023Assignee: GENEMEDICINE CO., LTD.Inventors: Chae Ok Yun, Yan Li
-
Publication number: 20220347242Abstract: The present invention relates to an anticancer composition comprising a tumor-specific oncolytic adenovirus and an immune checkpoint inhibitor. The recombinant adenovirus having IL-12 and shVEGF, or IL-12 and GM-CSF-RLX inserted therein, according to the present invention, exhibits an excellent anticancer effect by enhancing immune functions, and such anticancer effect has been confirmed to be notably enhanced through concomitant administration with an immune checkpoint inhibitor, and thus the present invention may be used as a key technique in the field of cancer treatment.Type: ApplicationFiled: May 16, 2022Publication date: November 3, 2022Applicant: GENEMEDICINE CO., LTD.Inventors: Chae Ok YUN, Hyo Min AHN
-
Publication number: 20220233718Abstract: An oncolytic adenovirus co-expressing interleukin (IL-12) and shVEGF and a composition for enhancing an anticancer effect are disclosed. The inventors confirmed that, when VEGF suppression and IL-12 expression are co-expressed in immunocompetent murine melanoma or kidney cancer models, an immune function is restored and an anticancer effect is improved. Particularly, it has been revealed that such an improved anticancer effect is associated with an increase in anticancer immunity, an increase in Thl cytokines and prevention of tumor-induced thymic atrophy, and therefore the applicability of a gene delivery system co-expressing IL-12 and shVEGF to cancer gene therapy was identified for the first time.Type: ApplicationFiled: January 28, 2022Publication date: July 28, 2022Applicant: Genemedicine Co., Ltd.Inventors: Chae Ok YUN, Hyo Min AHN
-
Patent number: 11364272Abstract: The present invention relates to an anticancer composition comprising a tumor-specific oncolytic adenovirus and an immune checkpoint inhibitor. The recombinant adenovirus having IL-12 and shVEGF, or IL-12 and GM-CSF-RLX inserted therein, according to the present invention, exhibits an excellent anticancer effect by enhancing immune functions, and such anticancer effect has been confirmed to be notably enhanced through concomitant administration with an immune checkpoint inhibitor, and thus the present invention may be used as a key technique in the field of cancer treatment.Type: GrantFiled: August 28, 2019Date of Patent: June 21, 2022Assignee: GENEMEDICINE CO., LTD.Inventors: Chae Ok Yun, Hyo Min Ahn
-
Publication number: 20220090025Abstract: Disclosed is a pH-sensitive and bioreducible polymer-virus complex which can destroy tumor cells more effectively by increasing the efficiency of virus transduction. A pH-sensitive and bioreducible polymer contains (i) an escapable portion from immune reactions, (ii) a chargeable portion having one or more amine groups and (iii) a bioreducible portion including one or more disulfide linkages. The and to a pharmaceutical composition containing the polymer-virus complex. Also disclosed are a pharmaceutical composition containing the pH-sensitive and bioreducible polymer-virus complex and methods for treating cancer in a subject, employing the composition.Type: ApplicationFiled: September 27, 2021Publication date: March 24, 2022Applicant: GENEMEDICINE CO., LTD.Inventors: Chae Ok YUN, Dayananda KASALA
-
Patent number: 11174465Abstract: The present invention relates to a pH-sensitive and bioreducible polymer-virus complex which can destroy tumor cells more effectively by increasing the efficiency of virus transduction, to a pH-sensitive and bioreducible polymer, and to a pharmaceutical composition containing the polymer-virus complex.Type: GrantFiled: October 21, 2016Date of Patent: November 16, 2021Assignee: GENEMEDICINE CO., LTD.Inventors: Chae Ok Yun, Dayananda Kasala
-
Patent number: 11000590Abstract: The present disclosure relates to a composition for transduction of a virus in a cell by using a crosslinked product of PEGylated magnetic nanoparticles and catechol grafted poly-L-lysine by application of an external magnetic field. When the composition is used, a virus may be delivered into cells more rapidly and efficiently than in intracellular uptake of a virus by CAR-mediated endocytosis.Type: GrantFiled: June 5, 2019Date of Patent: May 11, 2021Assignee: GENEMEDICINE CO., LTD.Inventors: Chae Ok Yun, Joung-Woo Choi
-
Publication number: 20210069253Abstract: The present invention relates to: recombinant adenoviruses, which have an excellent ability to be introduced into stem cells and can be easily introduced into stem cells even at a low concentration; stem cells comprising the same; a gene delivery composition; and a pharmaceutical composition. Stem cells into which adenoviruses are introduced, of the present invention, have excellent in vivo survivability and a treatment effect on tumor cells, and, when used as an anticancer drug, do not cause problems with respect to in vivo survival, hepatotoxicity and the like of stem cells so as to be particularly usable for systemic administration, and have an excellent anticancer effect even in small doses, thereby being widely usable as an anticancer drug using adenoviruses.Type: ApplicationFiled: December 12, 2018Publication date: March 11, 2021Applicant: GENEMEDICINE CO., LTD.Inventors: Chae Ok YUN, Yan LI
-
Publication number: 20210054332Abstract: A cell sheet for gene delivery is disclosed. Unlike conventional cell sheets for tissue regeneration, the disclosed cell sheet can be used as a local gene delivery system. Particularly when a virus is used as a gene delivery system, the virus can be proliferated within the cell sheet and acts topically within a therapeutic region. Thus, the cell sheet is superior in the prevention or treatment of cancer, the prevention of cancer recurrence or cancer metastasis, particularly the treatment of multifocal tumor even though the virus dose is remarkably lowered compared to the systemic administration or intratumoral injection of the virus.Type: ApplicationFiled: December 28, 2018Publication date: February 25, 2021Applicant: GENEMEDICINE CO., LTDInventors: Chae Ok YUN, Tae Geuk KIM
-
Patent number: 10722587Abstract: The present invention relates to a composition for intracellular delivery containing an adenovirus protein VI-derived peptide and an anti-cancer pharmaceutical composition containing the same. According to the present invention, the use of the peptide or peptide-polymer composite of the present invention improves intracellular delivery efficiency of a nucleic acid, a peptide, a poly-peptide, an antibody, a chemical material, or a virus. Therefore, the peptide or peptide-polymer composite of the present invention can be favorably used as an intracellular delivery system for various therapeutics.Type: GrantFiled: August 31, 2016Date of Patent: July 28, 2020Assignee: GENEMEDICINE CO., LTD.Inventor: Chae Ok Yun
-
Publication number: 20190388488Abstract: The present invention relates to an anticancer composition comprising a tumor-specific oncolytic adenovirus and an immune checkpoint inhibitor. The recombinant adenovirus having IL-12 and shVEGF, or IL-12 and GM-CSF-RLX inserted therein, according to the present invention, exhibits an excellent anticancer effect by enhancing immune functions, and such anticancer effect has been confirmed to be notably enhanced through concomitant administration with an immune checkpoint inhibitor, and thus the present invention may be used as a key technique in the field of cancer treatment.Type: ApplicationFiled: August 28, 2019Publication date: December 26, 2019Applicant: Genemedicine CO., LTD.Inventors: Chae Ok YUN, Hyo Min AHN
-
Publication number: 20190358277Abstract: The present invention relates to an anticancer composition comprising a recombinant adenovirus which expresses degradation factors for the extracellular matrix. The recombinant adenovirus according to the present invention exhibits an excellent anti-tumor effect by remarkably reducing the main structural components of the extracellular matrix in a tumor tissue, including collagen I, collagen III, fibronectin, elastin, and the like and highly expressing a therapeutic gene selectively only in tumor cells through viral proliferation. Particularly, when administered in combination with therapeutic materials, such as anticancer agents or immune checkpoint inhibitors, the recombinant adenovirus significantly increases the diffusion and distribution of the co-administered therapeutic materials in tumor tissues while allowing the exertion of the preexisting anticancer effects, thereby further improving an anti-cancer effect.Type: ApplicationFiled: June 10, 2019Publication date: November 28, 2019Applicant: Genemedicine CO., LTD.Inventors: Chae Ok YUN, Hyo Min AHN
-
Patent number: 10046067Abstract: The present invention relates to a novel gene delivery system and recombinant adenovirus comprising the decorin-encoding sequence to enhance transduction efficiency of transgenes, a pharmaceutical anti-tumor composition comprising the recombinant adenovirus, a pharmaceutical composition having improved tissue penetration potency and a pharmaceutical composition for treating a disease or disorder associated with accumulation of excess extracellular matrix.Type: GrantFiled: March 25, 2016Date of Patent: August 14, 2018Assignee: GENEMEDICINE CO., LTD.Inventors: Chae-Ok Yun, Joo Hang Kim
-
Patent number: 9920099Abstract: The present invention relates to a composition for preventing or treating cancer comprising Wnt decoy receptor. The composition of the present invention or the expression product thereof inhibits cancer generation, growth, proliferation and metastasis, and induces apoptosis of cancer cells, by binding to Wnt ligand and blocking ligand-receptor interactions, therefore may be effectively used as an anti-cancer agent.Type: GrantFiled: April 21, 2017Date of Patent: March 20, 2018Assignee: GENEMEDICINE CO., LTD.Inventors: Chae Ok Yun, Jung-Sun Lee
-
Patent number: 9689000Abstract: The present invention relates to a gene expression regulating sequence consisting of a combination of HRE, E2F and TERT, and to a gene delivery system having significantly improved selective tumor cell cytotoxicity using same, and more particularly, to a recombinant adenovirus. In addition, the present invention relates to a pharmaceutical antitumor composition comprising the recombinant adenovirus. The replication of the recombinant adenovirus of the present invention is tumor-specifically regulated by the novel gene expression regulating sequence of the present invention, thus enabling the recombinant adenovirus of the present invention to exhibit improved selective tumor cell cytotoxicity or apoptotic potential, and exhibit remarkably improved antitumor effects particularly in hypoxic conditions. In addition, the specific expression of the recombinant adenovirus in tumor cells may increase in vivo stability, and thus may induce greatly improved antitumor effects.Type: GrantFiled: June 28, 2011Date of Patent: June 27, 2017Assignee: GENEMEDICINE CO., LTD.Inventors: Chae Ok Yun, A-Rum Yoon
-
Patent number: 9657069Abstract: The present invention relates to a composition for preventing or treating cancer comprising Wnt decoy receptor. The composition of the present invention or the expression product thereof inhibits cancer generation, growth, proliferation and metastasis, and induces apoptosis of cancer cells, by binding to Wnt ligand and blocking ligand-receptor interactions, therefore may be effectively used as an anti-cancer agent.Type: GrantFiled: August 16, 2012Date of Patent: May 23, 2017Assignee: GENEMEDICINE CO., LTD.Inventors: Chae Ok Yun, Jung-Sun Lee
-
Patent number: 9468690Abstract: A novel gene delivery system and recombinant adenovirus includes a decorin-encoding sequence to enhance transduction efficiency of transgenes. A pharmaceutical anti-tumor composition includes the recombinant adenovirus, as well as a pharmaceutical composition having improved tissue penetration potency and a pharmaceutical composition for treating a disease or disorder associated with accumulation of excess extracellular matrix.Type: GrantFiled: February 24, 2006Date of Patent: October 18, 2016Assignee: GENEMEDICINE CO., LTD.Inventors: Chae-Ok Yun, Joo-Hang Kim